Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

@article{Stein2010TreatmentOF,
  title={Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.},
  author={Brady Lee Stein and Bruce D. Smith},
  journal={Clinical therapeutics},
  year={2010},
  volume={32 5},
  pages={804-20}
}
BACKGROUND Imatinib has been found to substantially improve outcomes in patients with chronic myeloid leukemia (CML) compared with previously available therapies. However, its use is complicated by development of resistance or drug intolerance, prompting dose escalation or a trial of dasatinib or nilotinib, the second-generation tyrosine kinase inhibitors (TKIs). OBJECTIVES This article reviews the mechanisms of TKI resistance; discusses the tolerability and efficacy of high-dose imatinib… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…